scholarly journals Provinces and territories agree to work together to purchase generic drugs and to expand use of bulk purchasing for brand-name drugs

2012 ◽  
Vol 145 (5) ◽  
pp. 202-203
Author(s):  
Kathie Lynas
Keyword(s):  
Generic Drugs ◽  
Brand Name ◽  
Brand Name Drugs

scholarly journals Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yuki Ito ◽  
Konan Hara ◽  
Byung-Kwang Yoo ◽  
Jun Tomio ◽  
Yasuki Kobayashi
Keyword(s):  
Generic Drugs ◽  
Income Group ◽  
High Income ◽  
Medical Expenditure ◽  
High Income Group ◽  
Brand Name ◽  
Income Groups ◽  
Additional Payment ◽  
Brand Name Drugs ◽  
Payment Rate

Abstract Background Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of such policy are unknown. We examined how patients’ choice between brand-name and generic drugs are affected by the unique income-based co-payment rates in Japan; 10% for general enrollees and 30% for those with high income among the elderly aged 75 and over. Methods We drew on cross-sectional price variation among commonly prescribed 311 drugs using health insurance claims data from a large prefecture in Japan between October 2013 and September 2014 to identify between-income-group differences in responses to differentiated payments. Results Running 311 multivariate logistic regression models controlling individual demographics, the median estimate indicated that high-income group was 3% (odds ratio = 0.97) less likely to choose a generic drug than the general-income group and the interquartile estimates ranged 0.92–1.02. The multivariate feasible generalized least squares model indicated high-income group’s higher likelihood to choose brand-name drugs than the general-income group without co-payment rate differentiation (p < 0.001). Such gap in the likelihood was attenuated by 0.4% (p = 0.027) with an US$1 increase in the difference in additional payment/month for brand-name drugs between income groups — no gap with US$10 additional payment/month. This attenuation was observed in drugs for chronic diseases only, not for acute diseases. Conclusions Income-based co-payment rates appeared to reduce disparity in access to brand-name drugs across income groups, in addition to reducing total medical expenditure among high-income group who shifted from brand-name drugs to generic ones due to larger drug price differences.

scholarly journals Comparison of the Properties of Brand-Name and Generic Nadifloxacin Creams

Medicina ◽  
2011 ◽  
Vol 47 (11) ◽  
pp. 89
Author(s):  
Yutaka Inoue ◽  
Miruto Matsumoto ◽  
Masayuki Kimura ◽  
Toru Tanaka ◽  
Ikuo Kanamoto
Keyword(s):  
Water Content ◽  
Absorption Spectroscopy ◽  
Infrared Absorption ◽  
Near Infrared ◽  
Generic Drugs ◽  
Infrared Absorption Spectroscopy ◽  
Brand Name ◽  
Yield Value ◽  
Lower Viscosity ◽  
Brand Name Drugs

Background and Objective. In external preparations, types and ratios of additives are not necessarily the same for brand-name drugs and generic drugs. Thus, the physicochemical properties of preparations may differ despite the fact that they contain the same ingredients or additives. This study examined differences in brand-name and generic versions of nadifloxacin (NFX) creams. Material and Methods. Three types of NFX creams (NFX-A, NFX-B, and NFX-C) were used. The viscosity of each preparation was determined, its yield value was calculated, and each preparation was subjected to light microscopy, x-ray powder diffraction, and near-infrared absorption spectroscopy. Results. Comparison of viscosity of different preparations revealed that NFX-B had a lower viscosity than NFX-A and NFX-C (14.5 vs. 24.6 and 17.9 Pa·s). NFX-B also had a lower yield value than NFX-A and NFX-C. Microscopy revealed that NFX-A and NFX-B had satisfactory emulsification although crystallization was observed with NFX-C. Near-infrared absorption spectroscopy revealed changes in the absorption spectra of NFX-B in comparison with those of NFX-A and NFX-C that were due to differences in water content and differences in fat and oil content. Conclusions. These findings confirmed that there were differences in the viscosity and flattening of NFX-A, NFX-B, and NFX-C. In addition, microscopy revealed differences in emulsification and it revealed the precipitation of NFX crystals in NFX-C. Near-infrared absorption spectroscopy revealed that differences in the type and amount of additives and water content in the creams had contributed to differences in the preparations.

Opinions of Czech general practitioners on generic drugs and substitution

Open Medicine ◽  
2014 ◽  
Vol 9 (6) ◽  
pp. 830-838
Author(s):  
Martin Dosedel ◽  
Josef Maly ◽  
Ales Kubena ◽  
Jiri Vlcek
Keyword(s):  
General Practitioners ◽  
Generic Substitution ◽  
Generic Drugs ◽  
Descriptive Statistics ◽  
Brand Name ◽  
The Czech Republic ◽  
Legal Rules ◽  
Item Questionnaire ◽  
Personal Experiences ◽  
Brand Name Drugs

AbstractThe aim of the study was to map and analyze general practitioners` opinions of, attitudes towards and experiences with generic drugs and generic substitution (GS) in the Czech Republic. General practitioners (GPs) who took part in the annual and regional professional conferences of the Society of General Practice in the period from November 2008 until March 2009 were asked to complete the 28-item questionnaire concerning the issue of generic drugs and GS. Questions were organized in 5 sections aimed at assessing the attitude towards GS, understanding the legislation and opinions on statements related to GS. All data were analyzed using descriptive statistics and correlations were tested by selected parametric and non-parametric tests. Total of 263 completed questionnaires were returned (mean age of 52.2 years (SD=13.7), 177 (67.3%) females and 248 (94.3%) GPs having a practice specialization). 99 (37.6%) respondents have considered generic drugs to be bioequivalent to the respective brand name drugs. 121 (46.0%) respondents believed that generic drugs are of lower quality than brand name drugs. None of respondent showed acquaintance with all the legal rules for GS. Awareness of the legislation and attitude towards GS correlated with the age (p<0.001). In conclusion, distrust among GPs in generic drugs derives from poor knowledge and personal experiences.

scholarly journals Perception of the value of generic drugs in São Paulo, Brazil

2016 ◽  
Vol 32 (2) ◽  
Author(s):  
Elene Paltrinieri Nardi ◽  
◽  
Marcos Bosi Ferraz
Keyword(s):  
Generic Drugs ◽  
Sao Paulo ◽  
Opinion Leaders ◽  
Health Plans ◽  
São Paulo ◽  
Brand Name ◽  
Government Hospitals ◽  
The University ◽  
Brand Name Drugs ◽  
Prefer Brand

Abstract The objective of this study was to assess the perceptions of opinion-leaders, patients and their accompanying family members or carers about generic drugs. Three groups of participants were surveyed: (i) 50 customers while they were visiting commercial pharmacies located in São Paulo city, Brazil, (ii) 25 patients and 25 companions while they were waiting at the university outpatient clinic, and (iii) 50 healthcare opinion-leaders from government, hospitals, health plans, academia, and pharmaceutical companies. The questions explored socio-demographic characteristics and perceptions regarding value attributes of generic drugs compared to brand name drugs. Respondents had an average age of 52 years and 53% were women. Respondents believed generic drugs to be cheaper than brand name drugs (97%), and 31% thought generic drugs to be less effective than brand name drugs. Also, generic drugs were perceived by 54% of respondents to be as safe as brand name drugs and 74% would prefer brand name drugs if there was no price difference. In conclusion, multiple factors may contribute to the decision to buy generic drugs; among these, perceived effectiveness, safety and price appear to be the most important factors.

Global Pharmaceuticals and East Africa

Give and Take ◽  
2019 ◽  
pp. 30-54
Author(s):  
Nitsan Chorev
Keyword(s):  
East Africa ◽  
Intellectual Property Rights ◽  
Structural Adjustment ◽  
Generic Drugs ◽  
Brand Name ◽  
Pharmaceutical Markets ◽  
Structural Adjustment Programs ◽  
Chinese Drugs ◽  
Originator Brand ◽  
Brand Name Drugs

This chapter traces the shift in the pharmaceutical markets in Kenya, Tanzania, and Uganda from markets dominated by originator (brand-name) drugs produced by western companies to markets dominated by generic drugs produced in the global South, most prominently, in India. The rise of Indian exports was not simply a consequence of conditions in India, as it is often suggested. In East Africa, it was also a consequence of market liberalization imposed through Structural Adjustment Programs (SAPs) on the three countries in the 1980s and 1990s. Specifically, the removal of foreign exchange restrictions—combined with inadequate regulation of the pharmaceutical market—allowed an unmonitored entry of drugs into the private market. The chapter then describes the ongoing efforts by multinational pharmaceutical companies to slow down that shift—especially by strengthening intellectual property rights. It also examines why reports on the prevalence of Chinese drugs in East Africa are greatly exaggerated.

scholarly journals Analysis of cost between branded medicines and generic medicines in a tertiary care hospital

2019 ◽  
Vol 8 (5) ◽  
pp. 1074
Author(s):  
Mohith N. ◽  
Nalini G. K. ◽  
Deepak P. ◽  
Sahana G. N. ◽  
Jayashree V. Nagaral ◽  
...  
Keyword(s):  
Generic Drugs ◽  
Tertiary Care ◽  
Generic Medicine ◽  
Care Hospital ◽  
Brand Name ◽  
Generic Medicines ◽  
Percentage Difference ◽  
The Mean ◽  
Mean Cost ◽  
Brand Name Drugs

Background: There is much debate regarding the importance of promoting the use of cheaper generic alternatives over brand-name drugs. While generic drugs have been noted to be comparable to brand-name drugs in their ability to treat conditions, significant debate surrounding their bioavailability or the concentration of the drug that reaches its site of action has arisen. Many experts continue to believe that generic and brand-name drugs are bioequivalent and equally viable options for effective drug treatment, as assumed in this review.Methods: Prices of commonly used branded and generic medicines in same concentration, dosage form and combination were compared with the help of Indian Drug Review, brochures of pharmaceuticals and pharmacies and Jan Aushadhi price list 2017. Mean of all the prices available of branded and generic medicine were calculated and the percentage difference in the mean costs of generic and branded medicines were calculated.Results: The mean cost of 47 branded medicines out of the selected 50 medicines was higher than their generic versions. Mean cost of 3 generic medicines was higher than branded ones. Percentage difference in the mean costs of branded and generic medicines varied from <10% to >70%.Conclusions: This study has shown a very noteworthy difference of prices between branded and generic drugs. Efforts should be taken to promote the generic medication. Misconception about low efficacy with generic drugs should be erased.

Sign in / Sign up

Export Citation Format

Share Document